Cover Image
Market Research Report
Product code 
1029820

Global Rapid Adenovirus Testing Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Rapid Adenovirus Testing Market - 2021-2028
Published: September 27, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global rapid adenovirus testing market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Adenovirus is one of the DNA viruses that are considered to be a major cause of febrile illness, primarily among children. Individuals and Infants with weak immune systems, cardiac disease or chronic respiratory problems are at higher risk of developing adenovirus infection. However, most infections are not severe. Adenovirus is a communicable infection, as it is an air-borne disease and can spread from an infected person to others by coughing and sneezing and close contact, such as shaking or touching hands.

Market Dynamics

The rapid adenovirus testing market growth is driven by the increasing advancements in the diagnosis of acute respiratory infections of adenovirus, the rising demand from SMEs and various industry verticals, macro-economic growth and growth in research and development of technologies are the prime factors of the market.

Increasing aid in diagnosis and treating of adenovirus, is expected to drive the growth in the forecast period

Adenoviruses are associated with various non-specific manifestations and clinical syndromes. Thus, diagnosis based upon clinical criteria alone is challenging. Diagnosis is most accurate when the infection shows outbreak symptoms or individuals show serious disease manifestations. Validation of adenovirus infection is essential for identifying the most appropriate treatment to establish a prognosis and initiate infection control measures using correct antiviral agents, thus making the diagnosis of these viruses a necessary procedure. The rapid detection and quantitation of adenovirus DNA, especially by a sensitive PCR technique, is expected to aid in diagnosing and treating adenovirus infections, particularly in immunocompromised patients. This, in turn, is expected to drive the growth of the rapid adenovirus testing market.

Surge in research and development of novel technologies, is expected to drive the growth in the forecast period

The growth in research and development of technologies for use in the diagnosis of acute respiratory infections of viral etiology is expected to propel the market's growth. For example, in 2014, DiaSorin launched its sixth LIAISON test for the qualitative detection of adenovirus in stool samples in markets outside the US and UK. This test adds to the five most important tests of the flight test panel already available. Markets (C. Conflicting Toxins A & B, C. Conflicting GDH Helicobacter, EHEC and Rotavirus).

Low sensitivity of rapid tests is likely to hamper the market growth

In general, the sensitivity of rapid tests is variable (median 70-75%) and lower than that of cell culture, while their specificity is high (median 90-95%). Because of the low sensitivity, false-negative results are a major concern with these tests.

COVID-19 Impact Analysis

Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.

COVID-19 has affected every market globally and has also impacted the global herpes simplex virus treatment market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.

Segment Analysis

The lateral flow immunochromatographic assay segment is expected to hold largest share in this market segment

Lateral flow immunochromatographic assays (LFIAs) are analytical devices used to detect the presence of one or more target analytes in a liquid sample. While LFIAs is one of the simplest and inexpensive types of immunoassays. For instance, The RIDA QUICK Rota/Adeno/Noro Combi is a single-step immunochromatographic lateral flow assay for the differential qualitative detection of Rotavirus, Adenovirus and Norovirus of Genogroups I and II in human stool specimens.

The polymerase chain reaction segment is expected to hold largest share in this market segment

More recently, cell culture has diagnosed the virus as an adenovirus that replicates efficiently in cell culture. Detection and amplification of adenoviral DNA by various PCR methods is becoming the most widely accepted experimental step for detecting adenoviral infection. In particular, rapid detection and quantification of adenoviral DNA by techniques such as PCR are expected to support the identification and therapeutic monitoring of adenoviral infection, especially in immunodeficient patients.

Moreover, Digital PCR (dPCR) is emerging as an important clinical tool. dPCR provides absolute nucleic acid quantitation at ultra-sensitivity without reference standards and opens up new opportunities for standardizing and comparing results between laboratories.

The hospitals segment is expected to hold largest share in this market segment

The hospitals segment held the largest market share, and the situation in the coming years is projected to be the same. This is because hospitals serve a far larger number of patients relative to diagnostic centers and clinics and developing healthcare infrastructure in emerging nations.

Geographical Analysis

North America region holds the largest market share of global rapid adenovirus testing market

North America is expected to gain significant traction due to growing public health concerns regarding various infectious diseases such as pneumonia associated with adenovirus infection. For instance, in 2014, the eighth cause of mortality in the U.S. was influenza and pneumonia together, as reported by the National Centre for Health Statistics. Manufacturers offer a variety of immunoassays for the detection of adenovirus antigens. The SD BIOLINE Rota / Adeno Ag test is one of Abbott's immunochromatographic analyses that qualitatively detects the presence of rotavirus or adenovirus antigens in human feces specimens.

For instance, in 2017, Abbott worked with UCSF (University of California, San Francisco) to detect new viruses and develop traits and diagnostic tools to resolve potential health threats caused by adenovirus. Herb and Marion Sandler's seed funding to the collaboration supported the development of the ViroChip. Supplier is also focused on improving the quality of analysis by performing surveillance projects in various hospitals, which are expected to create profitable growth opportunities in this market.

Competitive Landscape

The global rapid adenovirus testing market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Biopanda Reagents Ltd, CTK Biotech Inc, Creative Diagnostics, Biomerieux India Private Limited, Accuquik, SA Scientific, F. Hoffmann-La Roche Ltd, Diasorin S.P.A, Bio-Rad Laboratories Inc., QIAGEN, Intec Products Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, QIAGEN's NeuMo Dx ™ HAdV Quant Assay got CEIVD certificate on 9 July 2021 for automated testing for the detection of human adenovirus infection.

Key Companies to Watch

Bio-Rad Laboratories

  • Overview: Bio-Rad, founded in 1952, is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With employees, more than 7,800, headquarters Hercules, California, USA. Bio-Rad is among the top five life science companies globally, providing instruments, software, consumables, reagents, and content for cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. It is the world leader in clinical quality control products, services, and information systems, ensuring the accuracy and validity of clinical test results.
  • Product Portfolio: The Company's portfolio comprised of include life science research and clinical diagnostics.

Why Purchase the Report?

  • Visualize the composition of the rapid adenovirus testing market segmentation by assay, diagnosis, end-user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in rapid adenovirus testing market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of rapid adenovirus testing market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global rapid adenovirus testing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Rapid Adenovirus Testing Market - By Assay

  • Lateral Flow Immunochromatographic Assay
  • Immunogold Assay
  • PCR-Enzyme Hybridization Assay

Global Rapid Adenovirus Testing Market - By Diagnosis

  • Antigen Detection
  • Polymerase Chain Reaction (PCR)
  • Virus Isolation
  • Monoclonal Antibodies
  • Liposomes And Flow Cytometry
  • Chromatography
  • Gel Microdroplets

Global Rapid Adenovirus Testing Market - By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Clinics

Global Rapid Adenovirus Testing Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America
Product Code: DMBT4057

Table of Contents

1. Global Rapid Adenovirus Testing Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Rapid Adenovirus Testing Market - Market Definition and Overview

3. Global Rapid Adenovirus Testing Market - Executive Summary

  • 3.1. Market Snippet by Assay
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Global Rapid Adenovirus Testing Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing aid in diagnosis and treating of adenovirus
      • 4.1.1.2. Surge in research and development of novel technologies
    • 4.1.2. Restraints:
      • 4.1.2.1. Low sensitivity of rapid tests
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Rapid Adenovirus Testing Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Rapid Adenovirus Testing Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Rapid Adenovirus Testing Market - By Assay

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 7.1.2. Market Attractiveness Index, By Assay
  • 7.2. Lateral Flow Immunochromatographic Assay*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Immunogold Assay
  • 7.4. PCR-Enzyme Hybridization Assay

8. Global Rapid Adenovirus Testing Market - By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis
  • 8.2. Polymerase Chain Reaction (PCR)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Antigen Detection
  • 8.4. Virus Isolation
  • 8.5. Monoclonal Antibodies
  • 8.6. Liposomes And Flow Cytometry
  • 8.7. Chromatography
  • 8.8. Gel Microdroplets

9. Global Rapid Adenovirus Testing Market - By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Diagnostic Laboratories
  • 9.4. Clinics

10. Global Rapid Adenovirus Testing Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Global Rapid Adenovirus Testing Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Rapid Adenovirus Testing Market- Company Profiles

  • 12.1. Bio-Rad Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Biopanda Reagents Ltd
  • 12.3. CTK Biotech Inc
  • 12.4. Creative Diagnostics
  • 12.5. Biomerieux India Private Limited
  • 12.6. Accuquik
  • 12.7. SA Scientific
  • 12.8. F. Hoffmann-La Roche Ltd
  • 12.9. Diasorin S.P.A
  • 12.10. QIAGEN
  • 12.11. Intec Products Inc

LIST NOT EXHAUSTIVE

13. Global Rapid Adenovirus Testing Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us